TY - JOUR
T1 - A Pilot Study of Long‐Term Weekly Interferon‐β Administration for Chronic Hepatitis B
AU - Kagawa, Tatehiro
AU - Morizane, Toshio
AU - Saito, Hidetsugu
AU - Tsunematsu, Satoshi
AU - Tada, Shinichirou
AU - Kumagai, Naoki
AU - Tsuchimoto, Kanji
AU - Sugiura, Hitoshi
AU - Mukai, Makio
AU - Tsuchiya, Masaharu
PY - 1993/2
Y1 - 1993/2
N2 - Interferon‐β was given weekly for 24 wk, at a dose of 3 million units, intravenously, to 10 patients with chronic hepatitis B who were serologically positive for HBsAg and HBeAg. Their condition was followed for 6 months after the end of therapy. Both serum hepatitis B virus‐associated DNA‐polymerase activity and alanine aminotransferase level became significantly lower during therapy and during the 6 months after the end of therapy than at the beginning of therapy. In five of 10 patients, the seroconversion from HBeAg positive to anti‐HBe positive had occurred by 6 months after the end of therapy, and in four of these five patients, serum alanine aminotransferase level became normal. Weekly interferon‐β administration over 6 months seems effective in inducing seroconversion and in normalizing serum alanine aminotransferase level.
AB - Interferon‐β was given weekly for 24 wk, at a dose of 3 million units, intravenously, to 10 patients with chronic hepatitis B who were serologically positive for HBsAg and HBeAg. Their condition was followed for 6 months after the end of therapy. Both serum hepatitis B virus‐associated DNA‐polymerase activity and alanine aminotransferase level became significantly lower during therapy and during the 6 months after the end of therapy than at the beginning of therapy. In five of 10 patients, the seroconversion from HBeAg positive to anti‐HBe positive had occurred by 6 months after the end of therapy, and in four of these five patients, serum alanine aminotransferase level became normal. Weekly interferon‐β administration over 6 months seems effective in inducing seroconversion and in normalizing serum alanine aminotransferase level.
UR - http://www.scopus.com/inward/record.url?scp=0027397802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027397802&partnerID=8YFLogxK
U2 - 10.1111/j.1572-0241.1993.tb07507.x
DO - 10.1111/j.1572-0241.1993.tb07507.x
M3 - Article
C2 - 8424423
AN - SCOPUS:0027397802
SN - 0002-9270
VL - 88
SP - 212
EP - 216
JO - The American Journal of Gastroenterology
JF - The American Journal of Gastroenterology
IS - 2
ER -
